Obtain prior authorization when implant/device or related drugs are proposed

Certain procedures, implantable penile prostheses (CPT 54400-54417; HCPCS C1813, C2622) and injectable drug administrations (e.g., alprostadil codes J0270, J0275; collagenase J0775; vacuum device L7900) are covered only when the policy's selection/medical-necessity criteria are met and prior authorization may be required per plan.

• Penile prosthesis CPT codes 54400-54417 require documented failure of nonsurgical methods and other listed criteria.
• HCPCS codes C1813/C2622 and drug codes (J0270, J0275, J0775, L7900) are covered only if selection criteria in the policy are satisfied.
• Prior authorization may be required by the member’s benefit plan.

Confirm selection criteria before seeking coverage for listed HCPCS/J-codes

Coverage for the enumerated HCPCS and J-codes is contingent on meeting the policy's selection criteria and applicable ICD-10 diagnoses; confirm criteria are satisfied before billing or requesting authorization.

• Examples include C1813, C2622, J0270, J0275, J0775, J2440, J2760, L7900, L7902.
• Verify the associated ICD-10 diagnosis (e.g., N48.6, N52.01–N52.1, N52.31–N52.39) aligns with policy selection criteria.

Prior authorization and REMS verification required for Xiaflex

For Xiaflex (collagenase) therapy, prior authorization should confirm the FDA/REMS requirements and that the member meets the policy's Xiaflex selection criteria (palpable plaque, curvature thresholds, and injection limits).

• Xiaflex treatment course may include up to 4 cycles; each cycle consists of 2 injections and one penile modeling procedure.
• Administration must follow the Xiaflex REMS program; providers and facilities must be certified per REMS.
• Initial curvature requirement: ≥30 degrees; continuation request requires curvature ≥15 degrees and fewer than 8 total injections.

No PA specified in evidence summaries for LI‑ESWT

Background evidence summaries for LI‑ESWT and other investigational therapies do not specify prior authorization requirements; check plan-level rules before submitting requests.

• LI‑ESWT evidence is mixed and the policy background contains study summaries but no explicit PA language.
• Confirm with the member’s benefit plan whether prior authorization is needed for shock wave therapies.

Require PA and trial documentation for stem cell/exosome/PRP therapies

Stem cell, exosome, and platelet-rich plasma therapies are considered investigational with limited human data; prior authorization should require documentation of clinical-trial enrollment or justification and evidence of prior standard therapy attempts.

• Document trial phase, number of patients treated, follow-up duration, and validated outcome measures when proposing these therapies.
• Prior authorization is expected to require enrollment in an approved clinical trial or demonstration of failure of standard treatments.

No PA stated in this evidence excerpt

This evidence-summary fragment does not state a prior authorization requirement; follow plan-specific procedures for any authorization requests.

• The background provides evidence review only and contains no operational PA instructions.
• Contact payer operations or check plan documents for PA requirements.

No explicit PA requirements in final policy sections — verify plan terms

No prior authorization requirements are specified in the policy’s final administrative sections; always verify member benefit documents and plan terms for PA rules.

• Clinical Policy Bulletins do not guarantee coverage and do not replace benefit contract terms.
• Coverage and PA requirements remain subject to the member’s plan.

Document failed nonsurgical therapy before implantable prosthesis

Implantable penile prosthesis is medically necessary only after nonsurgical methods have failed or are contraindicated; document prior conservative treatments before seeking authorization or billing for prosthesis implantation.

• Confirm and document failure of nonsurgical therapies (e.g., PDE5 inhibitors, vacuum devices, injections) or a contraindication to them.
• Include required labs and absence of excluded conditions as specified in the implant criteria.

Start with PDE‑5 inhibitor therapy as first-line where appropriate

Clinical guidelines recommend initiating pharmacologic treatment with a PDE‑5 inhibitor in men without contraindications; document trial and response to PDE‑5 therapy when applicable.

• Choose a specific PDE‑5 inhibitor based on patient preference, cost, and adverse‑effect profile.
• Record treatment trials, dosing, and outcomes in the medical record.

Use established therapies before experimental/minimally supported options

Consider established, evidence-based therapies (e.g., intralesional interferon α‑2b or collagenase for Peyronie’s disease) before offering experimental or minimally supported options; document prior treatments and rationale for alternatives.

• Minimally invasive treatments with mixed/negative results (iontophoresis, ESWT, intra-lesional verapamil) lack strong evidence.
• Document why established options were unsuitable if proposing experimental therapies.

Background: oral PDE5 inhibitors generally considered first‑line

Background sections note oral PDE5 inhibitors are the usual first‑line therapy; no formal step‑therapy algorithm is specified in the policy, so document prior use when relevant to claims or PA.

• Record prior oral PDE5 inhibitor use and response when requesting coverage for advanced therapies.
• The policy provides clinical context but does not define mandatory sequencing rules.

Favor established rehabilitation methods over tacrolimus post‑prostatectomy

Given negative randomized trial data for oral tacrolimus after radical prostatectomy, prefer established rehabilitation approaches (PDE5 inhibitors, vacuum devices, penile rehabilitation) before novel agents; document prior standard treatments attempted.

• Tacrolimus failed to improve erectile function in an RCT; avoid using it as a preferred next-step without supportive evidence.
• Document trials of standard rehabilitation protocols and outcomes.

No step‑therapy sequence specified in this excerpt

This evidence excerpt does not describe any required sequencing or step‑therapy rules; follow the policy criteria and plan-level requirements when requesting coverage.

• The section summarizes literature and does not set operational step‑therapy mandates.
• Document prior therapies when relevant to utilization review.

No step‑therapy mandates present — check benefit documents

No formal step‑therapy requirements are stated in the provided sections; verify plan policies for any required sequencing prior to authorization or billing.

• Policy background and evidence reviews do not impose additional PA sequencing rules.
• Benefit plan terms remain authoritative for operational step‑therapy.

Include comprehensive history, physical, and diagnostic testing in documentation

Document a comprehensive history and physical, prior nonsurgical therapies, and relevant diagnostic testing (e.g., duplex Doppler with intracavernosal papaverine, pharmacologic response testing) when requesting authorization or billing for advanced interventions.

• Include medical/sexual history, psychosocial evaluation, and laboratory results (testosterone, prolactin, thyroid as indicated).
• For revascularization or implantable device requests, include objective vascular testing and documentation of failed conservative therapies.

Record physical exam details and objective curvature measurements

Clinical trials used physical exam details (plaque location, stretched penile length) and objective curvature measurement after pharmacologic erection; include these examination findings in the record when supporting Peyronie’s disease treatment requests.

• Record plaque location, stretched penile length, and goniometer‑measured curvature after papaverine injection.
• Include duplex ultrasound findings where performed.

Document objective curvature and patient‑reported outcomes for Xiaflex requests

For collagenase (Xiaflex) therapy, document objective curvature measurements (goniometer) and patient‑reported symptom bother scores and record the number of injection cycles and modeling procedures received.

• Document baseline curvature (≥30° required) and curvature at continuation requests (≥15° required).
• Record each injection and modeling procedure, with total injections not to exceed 8 per policy.

Record validated outcome measures (IIEF, EHS) at baseline and follow‑up

Use validated outcome measures (IIEF, IIEF‑EF/IIEF‑5, and EHS) at baseline and at prespecified follow‑up intervals to document treatment response for ED therapies.

• Record IIEF/IIEF‑EF and EHS scores at baseline and follow‑up (e.g., 1, 3–6, 12 months) as used in trials.
• Include treatment‑satisfaction or symptom bother questionnaires when available.

Provide trial details and validated outcomes when using investigational biologics

When reporting investigational biologic therapies (stem cell therapy, PRP), document trial phase, number of patients treated, follow‑up duration, validated outcome measures, and adverse events to support any coverage consideration.

• Include study protocol or clinical trial identifier if treatment is provided under a research protocol.
• Provide IIEF/EHS scores, duplex ultrasound results, and safety/adverse event reporting.

PRP evidence summaries do not specify additional documentation requirements

Background reviews of PRP and other investigational therapies summarize literature but do not list specific provider documentation requirements for authorization; rely on the documentation standards elsewhere in the policy and plan rules.

• The literature summaries note small study sizes and short follow‑up but do not specify operational documentation checklists.
• Follow general documentation guidance in the policy when submitting requests.

Providers maintain clinical responsibility; CPBs do not replace clinical judgment

Providers are responsible for medical decision‑making; Clinical Policy Bulletins are administrative tools to assist benefits administration and do not replace clinician judgment or plan contract terms.

• CPBs do not constitute offers of coverage and do not guarantee coverage.
• Always align clinical decisions with the patient's needs and benefit plan provisions.

Check plan exclusions — exclusions may cause denials

Some traditional medical plans exclude charges for treatment of sexual dysfunction; verify benefit plan exclusions before approving or billing for services, as exclusion may result in denial.

• Plan exclusions may exclude procedures for treatment of impotence under certain benefit plans.
• Check the member’s benefit description prior to authorization or claim submission.

Avoid billing disallowed HCPCS/ICD‑10 codes for listed indications

Certain HCPCS and ICD‑10 codes are identified in the policy as not covered for listed indications (e.g., codes for psychosexual dysfunction, drug‑induced ED); submitting these codes for excluded indications risks denial.

• Examples of ICD‑10 codes not covered for the CPB indications include F52.0, F52.21, F52.32, F52.4, N52.2, and R37.
• Verify the diagnosis codes match policy-covered indications before billing.

Confirm REMS certification for providers/facilities before Xiaflex approval

Xiaflex administration is restricted under an FDA REMS program; prior authorization or coverage decisions should confirm the treating provider and facility are REMS‑certified as required by the FDA.

• REMS requires participating health care professionals and health care facilities to be certified and trained for Xiaflex administration.
• Confirm REMS enrollment and certification before approving Xiaflex treatment requests.

Background sections do not list PA/billing triggers — verify plan rules

No explicit prior authorization or billing denial triggers are specified in some background fragments; nonetheless, lack of operational PA language does not supersede plan‑level authorization requirements.

• Background evidence sections summarize studies and do not list PA triggers.
• Always check the member's benefit plan for operational PA instructions.

Expect denial risk for novel/heterogeneous therapies due to insufficient evidence

Proposals for pelvic floor muscle training or novel biologic therapies (stem cell, exosome, PRP) face higher denial risk due to limited high‑quality evidence and heterogeneous protocols; include robust supporting data and trial documentation when requesting coverage.

• Small sample sizes, variable protocols, and short follow‑up in studies increase likelihood of denial for investigational approaches.
• Provide clinical-trial enrollment information or high‑quality evidence if available to mitigate denial risk.

Evidence-only fragments contain no operational authorization rules

Background and evidence‑only sections do not provide operational authorization details; rely on the policy's coverage criteria and plan provisions when preparing authorization requests.

• These sections summarize literature and are not substitutes for selection criteria or PA rules.
• Document adherence to the policy's explicit coverage criteria when applicable.

CPBs do not guarantee coverage — verify member contract terms

Clinical Policy Bulletins are administrative aids and are not guarantees of coverage; coverage determinations are governed by the member’s benefit plan and contract terms.

• Do not assume CPB language alone authorizes payment—confirm with the member’s plan documents.
• Coverage decisions remain subject to plan exclusions, prior authorization, and benefit limits.